Savara (NASDAQ:SVRA) Reaches New 12-Month High – Here’s What Happened

Shares of Savara Inc. (NASDAQ:SVRA) hit a new 52-week high during trading on Wednesday . The stock traded as high as $6.84 and last traded at $6.9350, with a volume of 4586018 shares changing hands. The stock had previously closed at $6.45.

Analysts Set New Price Targets

Several research analysts have issued reports on SVRA shares. Citigroup restated an “outperform” rating on shares of Savara in a report on Thursday, October 23rd. Lifesci Capital raised shares of Savara to a “strong-buy” rating in a research note on Tuesday, October 14th. Citizens Jmp cut their price target on shares of Savara from $11.00 to $10.00 and set a “market outperform” rating on the stock in a research report on Thursday, November 13th. Wall Street Zen raised shares of Savara from a “sell” rating to a “hold” rating in a research report on Saturday, November 15th. Finally, Wells Fargo & Company assumed coverage on Savara in a research note on Monday, October 20th. They set an “overweight” rating and a $7.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $8.29.

Savara Price Performance

The company has a debt-to-equity ratio of 0.32, a quick ratio of 7.65 and a current ratio of 7.65. The firm has a market capitalization of $1.36 billion, a PE ratio of -12.62 and a beta of 0.22. The business’s 50 day moving average is $4.45 and its two-hundred day moving average is $3.35.

Savara (NASDAQ:SVRA) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.01). Equities research analysts anticipate that Savara Inc. will post -0.45 earnings per share for the current fiscal year.

Institutional Trading of Savara

Hedge funds have recently made changes to their positions in the stock. F m Investments LLC increased its position in shares of Savara by 41.2% during the 2nd quarter. F m Investments LLC now owns 314,846 shares of the company’s stock valued at $718,000 after purchasing an additional 91,830 shares during the last quarter. Farther Finance Advisors LLC boosted its stake in Savara by 17.6% in the second quarter. Farther Finance Advisors LLC now owns 38,001 shares of the company’s stock worth $87,000 after buying an additional 5,687 shares in the last quarter. Emerald Advisers LLC grew its position in Savara by 14.4% during the second quarter. Emerald Advisers LLC now owns 3,534,368 shares of the company’s stock valued at $8,058,000 after acquiring an additional 444,155 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of Savara by 5.2% during the second quarter. Geode Capital Management LLC now owns 2,970,183 shares of the company’s stock worth $6,773,000 after acquiring an additional 147,946 shares in the last quarter. Finally, Affinity Asset Advisors LLC bought a new stake in shares of Savara in the 2nd quarter worth approximately $1,140,000. 87.93% of the stock is owned by institutional investors.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.